The IL4 Knockout ACHN Polyclonal Cells provide a CRISPR/Cas9-mediated loss-of-function model for the human IL4 gene in the ACHN renal adenocarcinoma cell background. Delivered as a polyclonal knockout cell population, these cells have undergone CRISPR/Cas9-mediated gene disruption without single-cell cloning, preserving population heterogeneity while eliminating IL-4 expression. This model enables dissection of IL-4-dependent signaling in a metastatic renal cell carcinoma (RCC) context.
The ACHN cell line was established from a malignant pleural effusion of a 22-year-old male with metastatic renal adenocarcinoma. It serves as a widely used in vitro model for renal cell carcinoma research, displaying aggressive characteristics including rapid proliferation and high invasiveness, and is extensively applied in tumor biology and therapeutic development studies.
Interleukin-4 (IL-4) is a key Th2 cytokine that exerts its effects by binding to a heterodimeric receptor composed of IL4R?? (IL4RA) and either the common gamma chain (IL2RG) or IL13RA1. Ligand engagement activates receptor-associated Janus kinases JAK1 and JAK3, which phosphorylate the latent transcription factor STAT6. Phosphorylated STAT6 homodimerizes and translocates to the nucleus to induce expression of target genes involved in Th2 differentiation, B cell class switching to IgE, and upregulation of cell surface molecules such as MHC II and CD23. The signaling cascade is subject to negative regulation by SOCS1 and is initiated by upstream signals including T cell receptor activation, IL-2 stimulation, and the transcription factors NFAT and GATA3, creating an autocrine loop that reinforces IL-4 production.
In the context of renal cell carcinoma, IL-4 signaling has been associated with modulation of tumor cell behavior and the immune landscape. ACHN cells endogenously express IL-4 receptor subunits and can respond to IL-4 stimulation with altered proliferative and secretory profiles. By abrogating IL-4 expression, the knockout model enables researchers to dissect tumor-intrinsic versus microenvironmental contributions of IL-4, particularly regarding immune cell recruitment, polarization, and resistance to checkpoint blockade. This system is thus instrumental for exploring IL-4 as a therapeutic target in RCC.
The IL4 Knockout ACHN Polyclonal Cells support a broad range of functional assays, including Western blotting for phosphorylated STAT6, ELISA-based measurement of IL-4 and IgE, quantitative RT-PCR profiling of STAT6-dependent genes, flow cytometric analysis of CD23 expression, and co-culture experiments with B lymphocytes to monitor IgE class switching. Additional applications encompass cell migration and invasion assays, high-throughput screening of JAK/STAT pathway inhibitors, and global transcriptomic analyses via RNA sequencing. For detailed technical specifications or ordering inquiries, please contact Ascent Research.
